Microfluidic Device Brings Single-Cell Technology to Bedside
By LabMedica International staff writers Posted on 06 Mar 2018 |

Image: The microfluidic control instrument performing a Drop-seq run (Photo courtesy of the New York Genome Center).
The complex architecture and associated higher-order function of human tissues relies on functionally and molecularly diverse cell populations. Defining the cellular subsets found in pathologic tissues provides insights into disease etiology and treatment options.
Traditional methods such as flow cytometry, which require a priori knowledge of cell type-specific markers, have begun to define this landscape, but fall short in comprehensively identifying cellular states in a tissue, with particular difficulty detecting extremely rare subpopulations.
Scientists at the New York Genome Center (New York, NY, USA) and their colleagues have facilitated broad access to single-cell sequencing by developing a 3D-printed, portable and low-cost microfluidic controller. They adapted this device to perform massively parallel single-cell RNA-seq (Drop-seq), observing metrics and performance that are indistinguishable from a study level Drop-seq setup.
The group used the instrument to profile joint synovial tissue from rheumatoid arthritis (RA) patients. RA is an autoimmune disease that affects 1% of the population and is associated with painful swelling in the joints. The precise cause of RA is undetermined and muddled by the diversity of cells found in the swollen joints of patients. The portability of the controller permitted patient samples to be processed on-site and immediately after surgery, minimizing handling and transport to optimize sample quality. The team collected samples from five RA patients totaling 20,387 cells and looked at the individual gene expression patterns for each cell.
By analyzing the complete dataset and searching for clusters of similar cells, the scientists identified 13 groups, representing both infiltrating immune and inflamed stromal populations. Of particular interest were distinct groups of fibroblasts with strikingly different gene expression patterns. They were able to validate the presence of these multiple groups using BD FACSAria II flow cytometry sorter, and discovered that they exhibited distinct localization patterns with the joint tissue as well. The instrument processes 1 mL of cells at a concentration of 150–200 cells/µL in about 30 minutes, generating over one million droplets at a generation rate of approximately 700 Hz.
Instructions and assembly manuals for the instrument can be found online at the popular microfluidics repository Metafluidics. The 3D-printed custom device, which, along with its electronic and pneumatic components, can be easily obtained and assembled for a total cost of about USD 600, a fraction of the cost of comparable commercial systems. The device occupies a small footprint as well, not much larger than a tissue box.
William Stephenson PhD, a Senior Research Engineer, and lead author of the study, said, “Most commercial microfluidic instruments are very costly; as a result, not every lab has access to exciting technology for single-cell analysis. We designed the instrument to perform droplet microfluidics and in particular Drop-seq, a massively parallel technology for single cell RNA-sequencing.” The study was published on February 23, 2018, in the journal Nature Communications.
Related Links:
New York Genome Center
Traditional methods such as flow cytometry, which require a priori knowledge of cell type-specific markers, have begun to define this landscape, but fall short in comprehensively identifying cellular states in a tissue, with particular difficulty detecting extremely rare subpopulations.
Scientists at the New York Genome Center (New York, NY, USA) and their colleagues have facilitated broad access to single-cell sequencing by developing a 3D-printed, portable and low-cost microfluidic controller. They adapted this device to perform massively parallel single-cell RNA-seq (Drop-seq), observing metrics and performance that are indistinguishable from a study level Drop-seq setup.
The group used the instrument to profile joint synovial tissue from rheumatoid arthritis (RA) patients. RA is an autoimmune disease that affects 1% of the population and is associated with painful swelling in the joints. The precise cause of RA is undetermined and muddled by the diversity of cells found in the swollen joints of patients. The portability of the controller permitted patient samples to be processed on-site and immediately after surgery, minimizing handling and transport to optimize sample quality. The team collected samples from five RA patients totaling 20,387 cells and looked at the individual gene expression patterns for each cell.
By analyzing the complete dataset and searching for clusters of similar cells, the scientists identified 13 groups, representing both infiltrating immune and inflamed stromal populations. Of particular interest were distinct groups of fibroblasts with strikingly different gene expression patterns. They were able to validate the presence of these multiple groups using BD FACSAria II flow cytometry sorter, and discovered that they exhibited distinct localization patterns with the joint tissue as well. The instrument processes 1 mL of cells at a concentration of 150–200 cells/µL in about 30 minutes, generating over one million droplets at a generation rate of approximately 700 Hz.
Instructions and assembly manuals for the instrument can be found online at the popular microfluidics repository Metafluidics. The 3D-printed custom device, which, along with its electronic and pneumatic components, can be easily obtained and assembled for a total cost of about USD 600, a fraction of the cost of comparable commercial systems. The device occupies a small footprint as well, not much larger than a tissue box.
William Stephenson PhD, a Senior Research Engineer, and lead author of the study, said, “Most commercial microfluidic instruments are very costly; as a result, not every lab has access to exciting technology for single-cell analysis. We designed the instrument to perform droplet microfluidics and in particular Drop-seq, a massively parallel technology for single cell RNA-sequencing.” The study was published on February 23, 2018, in the journal Nature Communications.
Related Links:
New York Genome Center
Latest Technology News
- Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
- Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
- Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
- AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
- Inexpensive DNA Coated Electrode Paves Way for Disposable Diagnostics
- New Miniature Device to Transform Testing of Blood Cancer Treatments
- Biosensing Advancement to Enable Early Detection of Disease Biomarkers at POC
- New POC Biosensing Technology Improves Detection of Molecular Biomarkers
- Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey
- AI-Assisted Non-DNA Based Test Identifies Viral Infections in Minutes
- AI Method Predicts Overall Survival Rate of Prostate Cancer Patients
- Breath Test to Enable Early Detection of Breast Cancer
- First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels
- Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more